ALPHA-9 THERANOSTICS APPOINTS SIMON PIMSTONE & MICHAEL REITERMANN TO BOARD OF DIRECTORS

May 15th, 2020, Vancouver, Canada: Alpha-9 Theranostics Inc. today announced that it has appointed two senior independent Non-Executive Directors to its Board.

Appointed are:

  • Simon Pimstone, MD, Founder and CEO of Xenon Pharmaceuticals, a Vancouver based NASDAQ limited company. Dr. Pimstone will serve as Chairman of the Board.
  • Michael Reitermann, previously Chief Operating Officer and Managing Board Member for Siemens Healthineers AG based in the U.S.

Ian McBeath, Chief Executive Officer for Alpha-9 Theranostics said today; “We are excited to have attracted and appointed two very experienced executives to our Board.  Simon brings to us his expertise in founding a successful biopharmaceutical company and taking it through to a public listing.  Michael will provide his expertise in managing an international med-tech company and his experience in running a radiopharmaceutical-based imaging business.  Both will play an active role as we seek to grow our Company and bring to market our unique cancer imaging and therapeutic products.”

About Alpha-9 Theranostics

Alpha-9 Theranostics is a clinical stage, radiopharmaceutical company based in Vancouver using molecularly targeted radiotherapy for the improved diagnosis and treatment of metastatic cancer.  The Company is developing new theranostic products based on breakthrough technology developed by the scientific founders and exclusively licensed from the University of British Columbia and BC Cancer. 

Alpha-9 is developing cancer imaging radiopharmaceuticals using novel technology that greatly simplifies the attachment of Fluorine-18 to cancer targeting biomolecules.  Currently two new imaging agents are being advanced, for neuroendocrine and prostate cancers.

Alpha-9’s first therapeutic product is a new radiopharmaceutical that targets advanced metastatic prostate cancer with the aim of achieving greater efficacy and an improved safety profile over first-generation products that are currently in clinical trials.

The Company is also developing a unique theranostic approach, where the same cancer seeking molecule can either be labelled with Fluorine-18 for PET imaging, or with a particle-emitting radioisotope to destroy cancer cells that have metastasized. 

About Molecularly Targeted Radiotherapy

Molecularly targeted radiotherapy can precisely deliver a therapeutic radionuclide directly to a cancer cell with minimal impact on healthy tissue.  This offers new hope for cancer patients whose disease has metastasized to vital organs, where surgery is not an option and use of systemic cancer drugs produces intolerable side-effects.

This news release contains certain forward-looking statements.  Actual results may differ materially from the statements made as a result of various factors, including, but not limited to, the inherent risks associated with drug research and development, difficulties or delays in development testing, changes in regulatory affairs, lack of therapeutic efficacy, unacceptable side-effects, the dependence on partners, the inability to raise sufficient finance, the appearance of competitors and other risks generally associated with the biopharmaceutical industry.

For further information contact:

Ian McBeath

Chief Executive Officer

Alpha-9 Theranostics Inc.

595 Burrard Street, Suite 2600

Vancouver, B.C.,

Canada, V7X 1L3

Telephone: (1)-778-231-2500

E mail:  imcb@alpha9tx.com

Web Site : www.alpha9tx.com